Vitro Biopharma, Inc.
CIK 793171fmd_180TSQ1N0J6DCS3Q3S4WZ5QCF9Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Nov 01, 2009 to Jul 31, 2026, 41 periods
| Line item | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 0 | 0 | 0 | 0 | 3 | 2 | 2 | 2 |
| Cost of revenue | 0 | 0 | (0) | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 1 | 2 |
| Research and development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Selling, general and administrative | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 6 | 7 | 6 |
| Total operating expenses | – | – | – | – | – | – | – | – | (3) | (3) |
| Operating income | (0) | (0) | (0) | (0) | (0) | (0) | (6) | (5) | (9) | (5) |
| Interest expense | (0) | (0) | 0 | (0) | 0 | 0 | 0 | 0 | 4 | 3 |
| Income before taxes | (0) | (0) | (0) | (0) | (0) | (0) | – | – | – | – |
| Income tax expense | – | – | 0 | 0 | 0 | – | – | – | – | – |
| Net income from continuing operations | – | – | (0) | (0) | (0) | – | – | – | – | – |
| Net income | (0) | (0) | (0) | (0) | (0) | (0) | (7) | (5) | (10) | (11) |
| Net income to common shareholders | – | – | – | – | – | – | (8) | (5) | (10) | (11) |